Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs

Neurology

Volumn 72, Issue 18, 2009, Pages 1588-1594

  Di Lorenzo, C ^a,g   Pierelli, F ^a,b   Coppola, G ^c   Grieco, G S ^d   Rengo, C ^d   Ciccolella, M ^e   Magis, D ^f   Bolla, M ^d,f   Casali, C ^a   Santorelli, F M ^e   Schoenen, J ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c IRCCS FONDAZIONE BIETTI   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g University Centre for Adaptive Disorders and Headache ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; RIBOFLAVIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENERGY METABOLISM; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PRIORITY JOURNAL; TREATMENT RESPONSE; BRAIN; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; INNATE IMMUNITY; METABOLISM; MIDDLE AGED; MIGRAINE; MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; BRAIN; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MIGRAINE WITH AURA; MITOCHONDRIAL DISEASES; MUTATION; RIBOFLAVIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649414741     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a41269     Document Type: Article

References (32)

1. Welch KM, Levine SR, D'Andrea G, Schultz LR, Helpern JA. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989;39:538-541.
2. Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992;42:1209-1214.
3. Montagna P, Cortelli P, Monari L, et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 1994;44:666-669.
4. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of highdose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology 1998;50:466-470.
5. Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004;11:475-477.
6. Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2006;26:361-372.
7. Majamaa K, Turkka J, Karppa M, Winqvist S, Hassinen IE. The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct. Neurology 1997;49:1331-1334.
8. Ojaimi J, Katsabanis S, Bower S, Quigley A, Byrne E. Mitochondrial DNA in stroke and migraine with aura. Cerebrovasc Dis 1998;8:102-106.
9. Majamaa K, Finnila S, Turkka J, Hassinen IE. Mitochondrial DNA haplogroup U as a risk factor for occipital stroke in migraine. Lancet 1998;352:455-456.
10. Wang Q, Ito M, Adams K, et al. Mitochondrial DNA control region sequence variation in migraine headache and cyclic vomiting syndrome. Am J Med Genet A 2004; 131:50-58.
11. Ruiz-Pesini E, Lapena AC, Diez-Sanchez C, et al. Human mtDNA haplogroups associated with high or reduced spermatozoa motility. Am J Hum Genet 2000;67:682- 696.
12. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd Edition (ICHD-II). Cephalalgia 2004;24 suppl 1:1-160.
13. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine, 2nd ed. Cephalalgia 2000;20:765-786.
14. Torroni A, Schurr TG, Cabell MF, et al. Asian affinities and continental radiation of the four founding Native American mtDNAs. Am J Med Genet 1993;53:563-590.
15. Baudouin SV, Saunders D, Tiangyou W, et al. Mitochondrial DNA and survival after sepsis: a prospective study. Lancet 2005;366:2118-2121.
16. Samuels DC, Carothers AD, Horton R, Chinnery PF. The power to detect disease associations with mitochondrial DNA haplogroups. Am J Hum Genet 2006;78:713-720.
17. Silberstein SD. Migraine. Lancet 2004;363:381-391.
18. Goadsby P. Recent advances in the diagnosis and management of migraine. BMJ 2006;332:25-29.
19. Schoenen J, Magis D. Herbal medicines and vitamins. In: Lipton RB, Bigal ME, eds. Migraines and Other Headache Disorders. New York: Informa Healthcare; 2006:363- 374.
20. Schoenen J. Pathogenesis of migraine: the biobehavioural and hypoxia theories reconciled. Acta Neurologica Belg 1994;94:79-86.
21. Hudson G, Carelli V, Spruijt L, et al. Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet 2007;81:228-233.
22. Jones MM, Manwaring N, Wang JJ, Rochtchina E, Mitchell P, Sue CM. Mitochondrial DNA haplogroups and age-related maculopathy. Arch Ophthalmol 2007; 125:1235-1240.
23. Fesahat F, Houshmand M, Panahi MS, Gharagozli K, Mirzajani F. Do haplogroups H and U act to increase the penetrance of Alzheimer's disease? Cell Mol Neurobiol 2007;27:329-334.
24. Chinnery PF, Taylor GA, Howell N, et al. Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology 2000;55:302-304.
25. Pyle A, Foltynie T, Tiangyou W, et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann Neurol 2005;57:564-567.
26. Niemi AK, Hervonen A, Hurme M, Karhunen PJ, Jylha M, Majamaa K. Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum Genet 2003;112:29-33.
27. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42: 2147-2152.
28. Bernsen PL, Gabreels FJ, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. J Neurol Sci 1993;118:181-187.
29. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006;1:CD004426.
30. Amo T, Yadava N, Oh R, Nicholls DG, Brand MD. Experimental assessment of bioenergetic differences caused by the common European mitochondrial DNA haplogroups H and T. Gene 2008;411:69-76.
31. Torroni A, Huoponen K, Francalacci P, et al. Classification of European mtDNAs from an analysis of three European populations. Genetics 1996;144:1835-1850.
32. Schoenen J. Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? Biomed Pharmacother 1996;50:71-78.